Appendix E - National Coverage Determinations Manual / VERTEPORFIN_-_Effective_April_1,_2004_(see_also_80.2.1_Ocular_Photodynamic_Therapy_(OPT))

Why This Topic Matters

Coverage decisions for verteporfin affect whether claims for ocular photodynamic therapy are payable under Medicare and whether related ocular indications must be handled through local coverage processes. Understanding the scope of this policy helps support accurate documentation review, medical necessity screening, and claim adjudication in ophthalmic care settings.

Article Sections

1. General

   Introduces verteporfin, its regulatory and pharmacologic context, and the general Medicare coverage framework for use with ocular photodynamic therapy.

2. Covered Indications

   Describes the covered diagnostic categories and the broad clinical circumstances tied to national coverage for ocular photodynamic therapy with verteporfin.

3. Noncovered Indications

   Summarizes the types of age-related macular degeneration uses that are not addressed as covered under this policy.

4. Other

   Notes additional ocular applications that may be considered under local contractor discretion rather than this national coverage article.